Latest DAFNA Capital Management LLC Stock Portfolio
DAFNA Capital Management LLC Performance:
2025 Q3: 23.91%YTD: 16.57%2024: -0.41%
Performance for 2025 Q3 is 23.91%, and YTD is 16.57%, and 2024 is -0.41%.
About DAFNA Capital Management LLC and 13F Hedge Fund Stock Holdings
DAFNA Capital Management LLC is a hedge fund based in LOS ANGELES, CA. On 30-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $542.7 Millions. In it's latest 13F Holdings report, DAFNA Capital Management LLC reported an equity portfolio of $404.8 Millions as of 30 Sep, 2025.
The top stock holdings of DAFNA Capital Management LLC are STXS, BIL, RVMD. The fund has invested 10.5% of it's portfolio in STEREOTAXIS INC and 9.9% of portfolio in SPDR S&P BIOTECH ETF.
The fund managers got completely rid off BLUEPRINT MEDICINES CORP (BPMC), ITEOS THERAPEUTICS INC (ITOS) and VYNE THERAPEUTICS INC (VYNE) stocks. They significantly reduced their stock positions in UROGEN PHARMA LTD (URGN), MINERALYS THERAPEUTICS INC and STOKE THERAPEUTICS INC (STOK). DAFNA Capital Management LLC opened new stock positions in SOLENO THERAPEUTICS INC (SLNO), RAPPORT THERAPEUTICS INC and ARS PHARMACEUTICALS INC (SBTX). The fund showed a lot of confidence in some stocks as they added substantially to NEKTAR THERAPEUTICS (NKTR), AQUESTIVE THERAPEUTICS INC (AQST) and LARIMAR THERAPEUTICS INC (LRMR).
The top stock holdings of DAFNA Capital Management LLC are STXS, BIL, RVMD. The fund has invested 10.5% of it's portfolio in STEREOTAXIS INC and 9.9% of portfolio in SPDR S&P BIOTECH ETF.
The fund managers got completely rid off BLUEPRINT MEDICINES CORP (BPMC), ITEOS THERAPEUTICS INC (ITOS) and VYNE THERAPEUTICS INC (VYNE) stocks. They significantly reduced their stock positions in UROGEN PHARMA LTD (URGN), MINERALYS THERAPEUTICS INC and STOKE THERAPEUTICS INC (STOK). DAFNA Capital Management LLC opened new stock positions in SOLENO THERAPEUTICS INC (SLNO), RAPPORT THERAPEUTICS INC and ARS PHARMACEUTICALS INC (SBTX). The fund showed a lot of confidence in some stocks as they added substantially to NEKTAR THERAPEUTICS (NKTR), AQUESTIVE THERAPEUTICS INC (AQST) and LARIMAR THERAPEUTICS INC (LRMR).
DAFNA Capital Management LLC Annual Return Estimates Vs S&P 500
Our best estimate is that DAFNA Capital Management LLC made a return of 23.91% in the last quarter. In trailing 12 months, it's portfolio return was 7.47%.
New Buys
| Ticker | $ Bought |
|---|---|
| soleno therapeutics inc | 3,582,800 |
| rapport therapeutics inc | 2,227,500 |
| mbx biosciences inc | 1,487,500 |
| ars pharmaceuticals inc | 1,412,020 |
| inspire medical systems inc | 1,276,240 |
| orchestra biomed holdings inc | 901,817 |
| celldex therapeutics inc new | 634,281 |
New stocks bought by DAFNA Capital Management LLC
Additions
| Ticker | % Inc. |
|---|---|
| nektar therapeutics | 449 |
| aquestive therapeutics inc | 260 |
| larimar therapeutics inc | 176 |
| compass therapeutics inc | 79.75 |
| mediwound ltd | 76.2 |
| alkermes plc | 29.88 |
| tandem diabetes care inc | 20.73 |
| day one biopharmaceuticals i | 13.65 |
Additions to existing portfolio by DAFNA Capital Management LLC
Reductions
| Ticker | % Reduced |
|---|---|
| urogen pharma ltd | -92.13 |
| mineralys therapeutics inc | -77.53 |
| stoke therapeutics inc | -66.18 |
| autolus therapeutics plc | -57.87 |
| foghorn therapeutics inc | -57.78 |
| brainsway ltd | -55.2 |
| ascendis pharma a/s | -54.35 |
| merus bv | -44.72 |
DAFNA Capital Management LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| gossamer bio inc | -1,045,400 |
| vyne therapeutics inc | -1,049,570 |
| adicet bio inc | -329,400 |
| inflarx nv | -158,000 |
| blueprint medicines corp | -21,632,000 |
| iteos therapeutics inc | -1,404,240 |
| palvella therapeutics inc | -977,064 |
| procept biorobotics corp | -172,800 |
DAFNA Capital Management LLC got rid off the above stocks
Sector Distribution
DAFNA Capital Management LLC has about 74.6% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 74.6 |
| Others | 25 |
Market Cap. Distribution
DAFNA Capital Management LLC has about 4.5% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 29.3 |
| SMALL-CAP | 25.9 |
| UNALLOCATED | 25.2 |
| MICRO-CAP | 15 |
| LARGE-CAP | 4.5 |
Stocks belong to which Index?
About 47.7% of the stocks held by DAFNA Capital Management LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 52.3 |
| RUSSELL 2000 | 45.7 |
| S&P 500 | 2 |
DAFNA Capital Management LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of DAFNA Capital Management LLC
DAFNA Capital Management LLC has 74 stocks in it's portfolio. About 57.1% of the portfolio is in top 10 stocks. TNDM proved to be the most loss making stock for the portfolio. MRUS was the most profitable stock for DAFNA Capital Management LLC last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACET | adicet bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ADCT | adc therapeutics sa | 0.12 | 122,081 | 488,324 | unchanged | 0.00 | ||
| ALEC | alector inc | 0.58 | 798,351 | 2,363,120 | reduced | -12.55 | ||
| ALGN | align technology inc | 0.34 | 11,000 | 1,377,420 | unchanged | 0.00 | ||
| ALKS | alkermes plc | 1.00 | 134,748 | 4,042,440 | added | 29.88 | ||
| ALLO | allogene therapeutics inc | 0.42 | 1,380,120 | 1,711,350 | unchanged | 0.00 | ||
| APRE | aprea therapeutics inc | 0.05 | 137,174 | 202,332 | unchanged | 0.00 | ||
| AQST | aquestive therapeutics inc | 0.71 | 512,589 | 2,865,370 | added | 260 | ||
| ARAY | accuray inc | 0.50 | 1,222,360 | 2,041,340 | unchanged | 0.00 | ||
| ATRC | atricure inc | 5.16 | 592,273 | 20,877,600 | unchanged | 0.00 | ||
| ATXS | astria therapeutics inc | 0.58 | 319,775 | 2,327,960 | reduced | -1.54 | ||
| AUTL | autolus therapeutics plc | 0.07 | 179,316 | 292,285 | reduced | -57.87 | ||
| AXGN | axogen inc | 3.27 | 742,282 | 13,242,300 | added | 0.07 | ||
| BCRX | biocryst pharmaceuticals inc | 0.41 | 218,255 | 1,656,560 | unchanged | 0.00 | ||
| BCYC | bicycle therapeutics plc | 0.12 | 64,492 | 499,168 | unchanged | 0.00 | ||
| BDTX | black diamond therapeutics i | 0.29 | 307,070 | 1,163,800 | reduced | -34.8 | ||
| BIL | spdr s&p biotech etf | 9.94 | 401,505 | 40,230,800 | reduced | -3.37 | ||
| BPMC | blueprint medicines corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CLDX | celldex therapeutics inc new | 0.16 | 24,518 | 634,281 | new | |||
| CMPS | compass pathways plc | 1.15 | 811,046 | 4,647,290 | unchanged | 0.00 | ||